吉西他滨联合卡培他滨治疗耐药转移性乳腺癌的临床观察

目的探讨吉西他滨和卡培他滨联合化疗治疗蒽环类和(或)紫杉类耐药的转移性乳腺癌的近期疗效和不良反应。方法 2008年3月至2011年3月应用吉西他滨联合卡培他滨治疗转移性乳腺癌38例,每3周为1个周期,所有患者均评估毒性,对至少用过2个周期化疗的患者评估疗效。结果 CR 3例,PR 13例,SD 14例,PD 8例,有效率(CR+PR)为42.1%(16/38),临床获益率(CR+PR+SD)为78.9%(30/38)。主要不良反应为骨髓抑制、手足综合征、胃肠道反应。Ⅲ～Ⅳ度的骨髓抑制发生率低,手足综合征及消化道反应以Ⅰ～Ⅱ度为主。结论吉西他滨联合卡培他滨对蒽环类和(或)紫杉类耐药的转移性乳腺癌有较好的治疗效果,且不良反应可以耐受。

Clinical Study of Chemotherapy with Gemcitabine and Capecitabine in Patients with Metastatic Breast Cancer

Objective To evaluate the efficacy and adverse reactions of chemotherapy with gemcitabine and capecitabine in metastatic breast cancer.Methods 38 metastatic breast cancer patients were treated with gemcitabine combined with capecitabine from March 2008 to March 2011.Patients who had received at least one course of chemotherapy were evaluated for toxicities and at least two courses for efficacy.Results In all the patients,there were 3 CR,13 PR,14 SD,8 PD.The overall effective（CR＋PR） rate was 42.1%（16/38）and clinical benefit（CR＋PR＋SD）was 78.9%（30/38）.The most common adverse effects were hand-foot syndrome,bone marrow suppression and gastrointestinal reaction.Grade Ⅲ～Ⅳ leucopenia was rare,and most hand-foot syndrome and gastrointestinal reaction were gradeⅠ～Ⅱ.Conclusion The combination of gemcitabine and capecitabine is effective and well-tolerated in metastatic breast cancer patients pretreated with antracyclines and /or taxanes.